生命科学资讯
生物技术与制药领域的最新动态
Lilly was the only pharma bidder for Ventyx
Insurance CEOs defend their businesses at House hearing
Former FDA deputies land at Lilly, AbbVie; Italy's Angelini has a new CEO
最高法院在让问题“酝酿”后,选择了希克玛的“瘦身标签”之争。
High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’
制药公司在2025年最后一季度减少了华盛顿游说支出
Drugmakers spent less on Washington lobbying in 2025's final quarter
Corcept药物在关键卵巢癌研究中延长患者生命
Corcept's drug extends patients' lives in key ovarian cancer study
中国初创药企Corxel融资2.87亿美元,推进口服GLP-1药物研发
China-founded pharma Corxel raises up to $287M for oral GLP-1
健康保险公司CEO赴华盛顿
Health insurance CEOs head to DC
罗氏将北卡罗来纳州工厂投资增至20亿美元;伦茨勒首席执行官卸任
Roche boosts NC factory investment to $2B; Rentschler CEO steps down
另一家生物制药公司在BioMarin的48亿美元交易前试图收购Amicus
Another biopharma tried buying Amicus before BioMarin's $4.8B deal
百时美施贵宝与Janux达成T细胞接合剂协议,首付款5000万美元。
Bristol Myers signs deal with Janux on T cell engager for $50M upfront
Erasca、Corvus、BioAge瞄准超5亿美元融资
Erasca, Corvus, BioAge target $500M+ offerings
欧盟药品价格谈判进展,各方说法不一
The status of EU drug price talks depends on who you ask
强生赞扬FDA新指南加速多发性骨髓瘤药物研发。
J&J praises new FDA guidance to speed development of multiple myeloma drugs
强生公司淡化MFN影响,预计2026年将实现强劲增长。
Johnson & Johnson brushes off MFN impact, sees strong growth for 2026
田边制药丸延缓血液疾病进展;enGene公司通过贷款增加至多1亿美元资金。
Tanabe pill delays blood disorder; enGene adds up to $100M from loans
IntraBio宣布罕见病药物通过三期临床试验,将寻求FDA批准。
IntraBio says rare disease drug passes Phase 3, will seek FDA approval
#JPM26:再生元、礼来、Summit就竞争对手涌入相同靶点发表看法
#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets
独家:Claim Health融资440万美元,助力家庭护理服务商收款无忧
Exclusive: Claim Health raises $4.4M to help home care providers get paid